[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.41.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 1988

Long-term Evaluation of 0.25% Levobunolol and Timolol for Therapy for Elevated Intraocular Pressure

Author Affiliations

From the University of Virginia School of Medicine, Charlottesville (Dr Allen); and the University of California (Dr Novack) and the Department of Ophthalmology Clinical Research, Allergan Inc (Dr Novack and Ms Batoosingh), Irvine, Calif. Drs Boozman, Carriker, and Foerster are in private practice in Rogers, Ark, Phoenix, and Colorado Springs, Colo, respectively.; Dr Novack and Ms Batoosingh are employed by Allergan Inc, Irvine, Calif, but have no proprietary interest in levobunolol.

Arch Ophthalmol. 1988;106(5):614-618. doi:10.1001/archopht.1988.01060130668023
Abstract

• In a one-year, double-masked, randomized study, the ocular hypotensive efficacy of twice-daily treatment with 0.25% levobunolol hydrochloride or timolol maleate was evaluated in 78 patients with glaucoma or ocular hypertension (phase 1). If intraocular pressure (IOP) was not well controlled during the study, the concentration of medication was increased to 0.5%, and the patient was followed up for an additional three months (phase 2). During phase 1, the mean IOP was reduced by 4.6 mm Hg in the timolol treatment group and by 5.1 mm Hg in the levobunolol treatment group. Seventy-one percent (29/41) of the patients in the timolol treatment group and 70% (26/37) of the patients in the levobunolol treatment group successfully completed phase 1. Of those patients who required the higher concentration of medication, 89% (8/11) in the timolol treatment group and 75% (3/4) in the levobunolol treatment group successfully completed phase 2. Higher concentration, however, did not produce greater IOP reduction. No statistically or clinically significant differences between the groups were noted in any of the efficacy or safety variables evaluated.

References
1.
Zimmerman TJ, Kaufman HE:  Timolol: Dose response and duration of action . Arch Ophthalmol 1977;95:605-607.Article
2.
Long D, Zimmerman T, Spaeth G, et al:  Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension . Am J Ophthalmol 1985;99:18-22.
3.
Uusitalo RJ, Palkama A, Stjernschantz J:  A study of two commercial preparations of timolol maleate with special reference to side effects . Acta Ophthalmol 1985;63:634-641.Article
4.
Afifi AA, Azen SP: Statistical Analysis: A Computer-Oriented Approach . Orlando, Fla, Academic Press Inc, 1972, pp 154-165.
5.
Fleiss J: Statistical Methods for Rates and Proportions . New York, John Wiley & Sons Inc, 1973, pp 117-118.
6.
Gross A, Clark V: Survival Distributions: Reliability Applications in the Biomedical Sciences . New York, John Wiley & Sons Inc, 1975, pp 45-46.
7.
Peto R, Pike MC, Armitage P, et al:  Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples . Br J Cancer 1976;35:1-39.Article
8.
Winer BJ: Statistical Principles in Experimental Design . New York, McGraw-Hill International Book Co, 1971, pp 518-539.
9.
Levobunolol Study Group:  Levobunolol: A beta-adrenergic antagonist effective in the longterm treatment of glaucoma . Ophthalmology 1985;92:1271-1276.Article
10.
Wandel T, Fishman D, Chen K, et al:  The efficacy of 0.25% levobunolol once-daily . Invest Ophthalmol Vis Sci 1987;27( (suppl) ):267.
11.
Richardson KT, Kurtzman C:  Evaluation of medical therapy in chronic glaucoma , in Cairns JE, Drance SM, Hoskins HD, et al (eds): Symposium on Glaucoma: Transactions of the New Orleans Academy of Ophthalmology . St Louis, CV Mosby Co, 1981, pp 322-331.
12.
Mills KB:  Blind randomized non-crossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the treatment of simple chronic glaucoma . Br J Ophthalmol 1983;67:216-219.Article
13.
Fraunfelder FT, Meyer SM:  Systemic side effects from ophthalmic timolol and their prevention . J Ocular Pharmacol 1987;3:177-184.Article
14.
Cinotti A, Cinotti D, Grant W, et al:  Levobunolol vs timolol for open-angle glaucoma and ocular hypertension . Am J Ophthalmol 1985;99:11-17.
15.
Zimmerman TJ, Kooner KS, Kandarakis AS, et al:  Improving the therapeutic index of topically applied ocular drugs . Arch Ophthalmol 1984;102:551-553.Article
×